Search the Newsreel

Form 8K Heartbeam Inc For: 14 August By Investing.com

This article reports that Heartbeam Inc. filed a Form 8K on August 14. The filing is available through Investing.com, which also provides current market data, including stock performance for BEAT, showing a -15.26% change. The content primarily serves as a notice of the filing …

Beam Global (NASDAQ: BEEM) delays 10-Q but guides to higher Q2 2026 revenue

Beam Global (NASDAQ: BEEM) has delayed its Form 10-Q filing for Q2 2026 due to resources being allocated to headquarters and manufacturing facility relocations, utilizing the five-day grace period. Despite the delay, the company provided preliminary, unaudited Q2 2026 figures, guiding to a 21% …

Beam Global's second-quarter briefing includes a Q&A session

Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake

ARK Investment Management LLC and Cathie Wood have reported a beneficial ownership of 9.95% in Beam Therapeutics Inc. (BEAM), totaling 10,234,862 shares. This disclosure, filed via a SCHEDULE 13G/A, indicates that ARK has significant voting and dispositive power over these shares. The filing also …

HeartBeam Inc (BEAT) (Q2 2026) Earnings Call Highlights: FDA Submission Advances and Commercial ...

HeartBeam Inc. (NASDAQ:BEAT) reported its Q2 2026 earnings, highlighting significant progress in FDA submissions for heart attack detection and initial commercial launches. Despite reporting a net loss of $5 million, the company reduced its operating cash outflow, extended its cash runway into 2027, and …

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due …

HeartBeam (BEAT): Strome group details 6.8% ownership and July–August share sales

Mark E. Strome and affiliated entities have filed an amended Schedule 13D for HeartBeam, Inc. (BEAT), reporting beneficial ownership of 3,764,200 shares, or 6.8% of the company's common stock. This includes a recent purchase of 750,000 shares in an underwritten public offering. The filing …

BEAT: FDA pre-submission for heart attack detection and commercial rollout drive growth, with costs down

Heartbeam, Inc. (BEAT) is advancing its heart attack detection initiatives, having submitted to the FDA and rapidly enrolled clinical participants. The company saw a decrease in operating cash outflows and net loss, and extended its cash runway into 2027, driven by a successful commercial …

HeartBeam Q2 Results: Net loss narrows to $5M, cash burn down 7%

HeartBeam Inc. reported a Q2 2026 net loss of $5 million, with its operating cash outflow decreasing by 7% quarter-over-quarter to $3.3 million. The company's cash and equivalents stood at $8.8 million, with a projected cash runway into 2027. HeartBeam is progressing with FDA …

Earnings call transcript: HeartBeam posts wider Q2 2026 loss, stock slips after hours

HeartBeam Inc. reported a wider-than-expected Q2 2026 loss of -$1.10 per share, significantly missing analyst estimates, causing its stock to slip after hours despite initial gains. The company highlighted progress in reducing operating cash burn, launching its HeartBeam card, and advancing clinical development for …

Why is Heartbeam stock sliding today?

Heartbeam Inc. (BEAT) stock slid 1.7% in after-hours trading after the company reported a wider-than-expected net loss of $0.10 per share for Q2 2026, missing analyst estimates. Despite lowering its full-year cash outflow guidance and completing enrollment for a key clinical study ahead of …

HeartBeam, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BEAT) 2026-08-13

HeartBeam (NASDAQ: BEAT) details Q2 loss, $11.5M equity raise and Nasdaq risk

HeartBeam Reports Second Quarter 2026 Results

HeartBeam, Inc. announced its financial and operational results for the second quarter ended June 30, 2026, highlighting significant advancements in heart attack detection clinical studies, including ahead-of-schedule enrollment in ALIGN-ACS and HEADSTART-ACS pilot studies. The company also reported progress on its initial commercial launch …

Beamtree Holdings Limited (ASX:BMT) Share Price Falls 4.35% as Stock Trades Within Daily Range

Beam Global’s Battery Design Paper Accepted for Presentation at IECON 2026 Data Center Track

Beam Global announced that its technical paper on a new battery design for AI data centers, developed with the University of Illinois at Chicago, has been accepted for presentation at IECON 2026. This innovation, titled "Designing Batteries for the AI Era," addresses the high …

Beam Global Designs Battery for Seconds-to-Minutes AI Data Center Surges

Beam Global (Nasdaq: BEEM) announced that its technical paper on a high-pulse-power battery architecture for AI data centers, developed with the University of Illinois at Chicago, has been accepted for presentation at IECON 2026. This technology aims to manage power surges and provide backup …

HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript

HeartBeam Inc. (NASDAQ: BEAT) reported a 7% decrease in operating cash outflow for Q2 2026, focusing on cost management and efficiency. The company submitted a pre-submission to the FDA for heart attack detection, with clinical trials expected by year-end, and is gaining momentum with …

Beam Global expected to post a loss of 20 cents a share - Earnings Preview

Beam Global is expected to report a loss of 20 cents per share in its upcoming earnings release. This information is provided as an earnings preview.

Beamr Begins First Structured Engagement With Global Autonomous Vehicle Program

Beamr (NASDAQ: BMR) announced its first structured engagement with a global autonomous vehicle program, highlighting progress in AVs, media and entertainment, and reporting first-half 2026 financials. Despite a 17% decrease in revenue to $0.9 million and a widened net loss of $4.4 million for …

Beamr Imaging Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026

Beamr Imaging Ltd. (BMR) stock price, news, quote and history

Equities Analysts Offer Predictions for BEAM Q3 Earnings

Beamr reports H1 revenue decline, advances AV compression tech

Beamr Imaging Ltd. reported a 17% revenue decline in the first half of 2026, totaling $0.9 million, and a net loss of $4.4 million. Despite the financial downturn, the company made significant advancements in autonomous vehicle compression technology, including a new service called Beamr …

Beamr Imaging (NASDAQ: BMR) revenue drops as R&D and sales spending rise

Beamr Imaging Ltd. (NASDAQ: BMR) reported a 17% decrease in H1 2026 revenue to $884 thousand, down from $1.07 million a year earlier, primarily due to the absence of a one-time project in 2025. The company's net loss widened to $4.40 million from $3.19 …

Beamr Issues Q2-2026 CEO Letter to Shareholders: Expanding Our Reach into Autonomous Vehicle Teams

Beamr Imaging Ltd. (NASDAQ: BMR) issued its Q2-2026 CEO Letter to Shareholders, detailing its progress in expanding into the autonomous vehicle (AV) market and strengthening its media and entertainment business. The company highlighted its first structured engagement with a global AV program and ecosystem …

Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM)

Analysts have issued a major negative revision to Beam Therapeutics Inc.'s near-term revenue forecasts for 2026, anticipating a significant decline in sales while losses per share are expected to balloon. Despite the drastic revenue downgrade, the consensus price target remains unchanged, suggesting analysts do …

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy

H.C. Wainwright has reiterated a Buy rating and an $80.00 price target for Beam Therapeutics Inc. (NASDAQ:BEAM), representing a 64% potential upside. The company is advancing several clinical programs, including BEAM-302 for AATD-associated lung disease, ristoglogene autogetemcel (risto-cel) with a biologics license application expected …

Beam Global (BEEM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC

(BEAM) and the Role of Price-Sensitive Allocations

This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), highlighting a mid-channel oscillation pattern and an exceptional 62.6:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and time horizons. The analysis suggests a near-term strong …

Beam Therapeutics (NASDAQ:BEAM) Rating Lowered to "Sell" at Wall Street Zen